TREANDA®

Drug Information Related Patent

Hold Company

Teva Pharmaceuticals

Learn More

Dosage and Administration

POWDER;IV (INFUSION)

Specification

100MG/VIAL; 25MG/VIAL

Indication

TREANDA® is indicated for the treatment of chronic lymphocytic leukemia. It can also be used in patients with indolent B-cell non-Hodgkin's lymphoma who have progressed during or within 6 months of rituximab or rituximab-containing therapy.

Use

Instructions for Use

API

BENDAMUSTINE HYDROCHLORIDE

API Structure

We Supply

BENDAMUSTINE HYDROCHLORIDE

Note:

Facility GMP
Product GMP
ASMF/Canada-HC/CDE

null

Note:

null

Note:

null

Drug Patent

Patent No	Expiration Date
8436190	2030/10/26
8436190*PED	2031/4/26
8445524	2029/3/26
8445524*PED	2029/9/26
8609863	2026/1/12
8609863*PED	2026/7/12
8669279	2029/3/26
8669279*PED	2029/9/26
8791270	2026/1/12
8791270*PED	2026/7/12
8883836	2029/3/26
8883836*PED	2029/9/26
8895756	2026/1/12
8895756*PED	2026/7/12
9533955	2029/3/26
9533955*PED	2029/9/26

API Patent

Patent No	Expiration Date
8445524	2029/3/26
8445524*PED	2029/9/26
8669279	2029/3/26
8669279*PED	2029/9/26
8883836	2029/3/26
8883836*PED	2029/9/26
9533955	2029/3/26
9533955*PED	2029/9/26

Note: The patent information provided herein is derived solely from publicly available data in the FDA Orange Book (or other cited sources) and is presented for general informational purposes only. Actual patent status may vary based on jurisdictional rulings, regulatory extensions or other factors.